Direxion Daily Biotech Top 5 Bull 2X ETF(TBXU.US)

Last Updated 19:00:00 ET
longbridge loading
Company Encyclopedia
View More
name
Direxion Daily Biotech Top 5 Bull 2X ETF
TBXU.US
News
View More

Priovant Announces Positive Phase 2 Results For Brepocitinib In Cutaneous Sarcoidosis (Cs)

Feb 6 (Reuters) - Priovant:* PRIOVANT ANNOUNCES POSITIVE PHASE 2 RESULTS FOR BREPOCITINIB IN CUTANEOUS SARCOIDOSIS (CS)* PRIOVANT - BREPOCITINIB WELL TOLERATED WITH NO SERIOUS ADVERSE EVENTS* PRIOVANT: PLANS TO PROGRESS CS TO A PIVOTAL PROGRAM WITH A PHASE 3 STUDY STARTING IN CALENDAR YEAR 2026 FOLLOWING ENGAGEMENT WITH FDA Source text: Further company coverage:

Reuters·
US
BBH
+1.75%
US
XBI
+3.35%
US
FBT
+1.89%
Reuters·
US
BBH
+1.75%
US
XBI
+3.35%
US
FBT
+1.89%

The IPO Buzz: AgomAb Therapeutics (AGMB) Prices IPO at $16 & Joins ‘The Mid-Point Club’

AgomAb Therapeutics NV (AGMB) has priced its IPO at $16.00, aligning with the mid-point trend, raising $200 million by offering 12.5 million American Depositary Shares. The funds will support Phase 2 trials for its Crohn’s disease pill and inhaled treatment for pulmonary fibrosis. Despite backing from Pfizer, AgomAb reported a net loss of $65.98 million with no product revenue for the past year. The shares are set to begin trading on NASDAQ.

IPO Scoop·
US
BIB
+4.87%
US
PBE
+1.63%
US
BBH
+1.75%
IPO Scoop·
US
BIB
+4.87%
US
PBE
+1.63%
US
BBH
+1.75%

Novavax Inc. Stock Underperforms Thursday When Compared To Competitors

Novavax Inc. (NVAX) shares fell 4.84% to $7.87 on Thursday, marking the fifth consecutive day of losses. The stock is now 26.07% below its 52-week high of $10.64. In contrast, competitors like Johnson & Johnson and Merck saw gains, while Pfizer experienced a slight decline. The NASDAQ Composite Index dropped 1.59% and the Dow Jones Industrial Average fell 1.20%. Trading volume was below the 50-day average.

Dow Jones·
US
BBH
+1.75%
US
FBT
+1.89%
US
TBXU
0.00%
Dow Jones·
US
BBH
+1.75%
US
FBT
+1.89%
US
TBXU
0.00%

Gilead Sciences Inc. Stock Outperforms Competitors On Strong Trading Day

Gilead Sciences Inc. (GILD) shares rose 2.15% to $149.37 on a weak trading day for the market, marking its fifth consecutive gain and a new 52-week high. In contrast, the S&P 500 fell 1.23% and the Dow Jones dropped 1.20%. Gilead outperformed competitors like Johnson & Johnson, which rose 1.42%, while Pfizer fell 1.08% and Abbott rose 0.81%. Trading volume reached 9.1 million, exceeding the 50-day average of 7.2 million.

Dow Jones·
US
BIB
+4.87%
US
IBBQ
+2.56%
US
TBXU
0.00%
Dow Jones·
US
BIB
+4.87%
US
IBBQ
+2.56%
US
TBXU
0.00%

Bristol Myers Squibb Co. Stock Outperforms Competitors On Strong Trading Day

Bristol Myers Squibb Co. (BMY) shares rose 2.91% to $57.62 on a mixed trading day, marking its fourth consecutive gain. The stock remains 9.02% below its 52-week high of $63.33. In comparison, Johnson & Johnson (JNJ) increased by 0.59%, Pfizer Inc. (PFE) by 3.92%, while Abbott Laboratories (ABT) fell by 0.75%. Trading volume reached 21.7 million, surpassing the 50-day average of 14.4 million.

Dow Jones·
US
IBB
+2.35%
US
TBXU
0.00%
US
FBT
+1.89%
Dow Jones·
US
IBB
+2.35%
US
TBXU
0.00%
US
FBT
+1.89%
© 2026 Longbridge｜Disclaimer